×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
上海药物研究所 [3]
山东大学 [2]
合肥物质科学研究院 [2]
西安交通大学 [1]
吉林大学白求恩第一医... [1]
中国医学科学院 北京... [1]
更多...
内容类型
期刊论文 [10]
发表日期
2022 [2]
2019 [1]
2018 [2]
2017 [2]
2016 [2]
2013 [1]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共10条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis
期刊论文
ANNALS OF PALLIATIVE MEDICINE, 2022, 卷号: 11
作者:
Lei, Lei
;
Chen, Rucheng
;
Fan, Lei
;
Zheng, Weijun
;
Wang, Xiaojia
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2022/12/23
Breast cancer
nanoparticle-albumin-bound paclitaxel (Nab-P)
taxanes
meta-analysis
Efficacy and safety of radiotherapy combined with raltitrexed and irinotecan for treating unresectable recurrent colorectal cancer: a single-arm phase II trial
期刊论文
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022
作者:
Li, Xinghui
;
Shen, Jinwen
;
Xia, Fan
;
Zhu, Ji
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2022/12/23
Colorectal cancer
local recurrence
intensity-modulated radiotherapy
irinotecan
raltitrexed
A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
期刊论文
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 卷号: 57, 期号: 3
作者:
Li, Cuiyun
;
Zhang, Hong
;
Zhu, Xiaoxue
;
Wei, Haijing
;
Chen, Hong
收藏
  |  
浏览/下载:29/0
  |  
提交时间:2019/12/05
biosimilar
phase I
IBI305
bevacizumab
pharmacokinetics
Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more
期刊论文
FUTURE ONCOLOGY, 2018, 卷号: 14, 期号: 21, 页码: 2131-2138
作者:
Chen, Dawei
;
Song, Xinyu
;
Zhang, Yan
;
Kong, Li
;
Wang, Haiyong
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2019/12/11
adverse events
bevacizumab dose
intrapleural
malignant pleural
effusion
NSCLC
outcomes
Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer
期刊论文
2018, 卷号: 9, 期号: 5, 页码: 613-620
作者:
Zhai, Xiaoyu
;
Hong, Ruoxi
;
Fan, Ying
;
Yuan, Peng
;
Wang, Jiayu
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2020/01/03
Anti-angiogenic therapy
bevacizumab
metastatic breast cancer
1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G(2)/M phase
期刊论文
ACTA PHARMACOLOGICA SINICA, 2017, 卷号: 38, 期号: 4, 页码: 561-570
作者:
Peng, Chun
;
Qi, Xin-ming
;
Miao, Ling-ling
;
Ren, Jin
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2019/01/08
1,2:5,6-dianhydrogalactitol
human glioblastoma
cell cycle arrest
p53-p21 cascade
CDC25C-CDK1 cascade
radiosensitivity
xenografted tumors
1256dianhydrogalactitolinhibitshumangliomacellgrowthinvivoandinvitrobyarrestingthecellcycleatg2mphase
期刊论文
actapharmacologicasinica, 2017, 卷号: 38, 期号: 4, 页码: 561
作者:
Peng Chun
;
Ql Xinming
;
Miao Lingling
;
Ren Jin
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2020/07/01
NEWLY-DIAGNOSED GLIOBLASTOMA
DNA-DAMAGE
RANDOMIZED-TRIAL
DIANHYDROGALACTITOL
TEMOZOLOMIDE
P53
CANCER
TUMORS
BEVACIZUMAB
COMBINATION
1,2:5,6-dianhydrogalactitol
human glioblastoma
cell cycle arrest
p53-p21 cascade
CDC25C-CDK1 cascade
radiosensitivity
xenografted tumors
DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo
期刊论文
ACTA PHARMACOLOGICA SINICA, 2016, 卷号: 37, 期号: 3, 页码: 398-407
作者:
Li, Meng-yuan
;
Lv, Yong-cong
;
Tong, Lin-jiang
;
Peng, Ting
;
Qu, Rong
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2019/01/08
DW10075
VEGF/VEGF receptor inhibitor
antitumor
angiogenesis
U87-MG human glioblastoma
Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: A case report and literature review
期刊论文
ONCOLOGY LETTERS, 2016, 卷号: 11, 期号: 5, 页码: 2981-2986
作者:
Liu, Pengfei
;
Yao, Qingyu
;
Li, Na
;
Liu, Yongliang
;
Wang, Yuguo
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2019/12/17
neurofibromatosis type 2
bevacizumab
vascular cendothelial growth
factor
vestibular schwannomas
Retinal angiomatous proliferation responds safely to a double dose (1.0?mg) of ranibizumab
期刊论文
CLINICAL AND EXPERIMENTAL OPTOMETRY, 2013, 卷号: 96, 期号: [db:dc_citation_issue], 页码: 112-116
作者:
Hsu, Tsui-Kang
;
Liu, Jorn-Hon
;
Lei, Jianqin
;
Chao, Hsiao-Ming
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2019/12/03
ranibizumab
bevacizumab
photodynamic therapy
age-related macular degeneration
retinal angiomatosis
retinal haemorrhage
choroidal neovascularisation
©版权所有 ©2017 CSpace - Powered by
CSpace